Study summary
Palbociclib held chordoma stable in about 4 in 10
39%disease control rate
What was tested
Palbociclib, a CDK4/6 inhibitor, for advanced chordoma with loss of the CDKN2A gene.
What they found
- Disease was controlled in 39%, but no tumors shrank.
- Median survival was 24.6 months.
What it means
Modest activity; may be combined with other drugs in future trials.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.